Meeting
2019 ASCO Annual Meeting
A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors.
Authors
Claudia Proto
Fondazione IRCCS-Istituto Nazionale dei Tumori, Milan, Italy
Claudia Proto , Arsela Prelaj , Carla Verri , Diego Signorelli , Giuseppe Lo Russo , Roberto Ferrara , Giulia Galli , Benedetta Trevisan , Mensah Mavis , Filippo G. De Braud , Marina Chiara Garassino , Gabriella Sozzi , Mattia Boeri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9096)
DOI
10.1200/JCO.2019.37.15_suppl.9096
Abstract #
9096
Poster Bd #
419
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Outcomes in patients with advanced non-small cell lung cancer (aNSCLC) and high PD-L1 expression treated with immune checkpoint inhibitor monotherapy: An FDA-pooled analysis.
First Author: Sujay Yogesh Shah
Poster
2021 ASCO Annual Meeting
Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.
First Author: Noura J. Choudhury
Poster
2024 ASCO Annual Meeting
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.
First Author: Lingzhi Hong
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte